HER1-based vaccine: simultaneous activation of humoral and cellular immune response

The human epidermal growth factor receptor 1 (HER1) is a tumor associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune-escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research